secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001193125-23-146203
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan enters ATM equity offering with Wedbush, up to 2% commission
------------------------------------------------------------------

- Entered Sales Agreement with Wedbush Securities for at-the-market issuance of common stock.
- Commission of up to 2.0% of gross proceeds; Company sets sale parameters.
- Shelf registration statement (333-268260) declared effective May 16, 2023; prospectus supplement filed.
- No obligation to sell; either party may suspend or terminate offering on notice.
- Sales may also be made to Wedbush as principal at agreed prices; customary indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523146203/0001193125-23-146203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523146203/d502216d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-146203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer